Use of sialylated or sulfated derivatives and acrylamide copolymers of Gal?1,3GalNAc?- and GalNAc?- to determine the specificities of blood group T- and Tn-specific lectins and the copolymers to measure anti-T and anti-Tn antibody levels in cancer patients

1995 ◽  
Vol 12 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Yongxin Chen ◽  
Rakesh K. Jain ◽  
E. V. Chandrasekaran ◽  
Khushi L. Matta
Keyword(s):  
Cancer Patients ◽  
Blood Group ◽  
Antibody Levels ◽  
Acrylamide Copolymers

Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin

2000 ◽  
Vol 18 (3) ◽  
pp. 574-574 ◽  
Author(s):  
S. von Mensdorff-Pouilly ◽  
A.A. Verstraeten ◽  
P. Kenemans ◽  
F.G. M. Snijdewint ◽  
A. Kok ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Humoral Response ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Antibody Levels ◽  
Pretreatment Serum ◽  
Test Result ◽  
Disease Specific

PURPOSE: Polymorphic epithelial mucin (PEM or MUC1) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma. The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease.MATERIALS AND METHODS: We measured immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to MUC1 with an enzyme-linked immunoassay (PEM.CIg), which uses a MUC1 triple-tandem repeat peptide conjugated to bovine serum albumin, in pretreatment serum samples obtained from 154 breast cancer patients (52 with stage I disease and 102 with stage II) and 302 controls. The median disease-specific survival time of breast cancer patients was 74 months (range, 15 to 118 months). A positive test result was defined as MUC1 IgG or IgM antibody levels equal to or greater than the corresponding rounded-up median results obtained in the total breast cancer population.RESULTS: A positive test result for both MUC1 IgG and IgM antibodies in pretreatment serum was associated with a significant benefit in disease-specific survival in stage I and II (P = .0116) breast cancer patients. Positive IgG and IgM MUC1 antibody levels had significant additional prognostic value to stage (P = .0437) in multivariate analysis. Disease-free survival probability did not differ significantly. However, stage II patients who tested positive for MUC1 IgG and IgM antibody and who relapsed had predominantly local recurrences or contralateral disease, as opposed to recurrences at distant sites in the patients with a negative humoral response (P = .026).CONCLUSION: Early breast cancer patients with a natural humoral response to MUC1 have a higher probability of freedom from distant failure and a better disease-specific survival. MUC1 antibodies may control hematogenic tumor dissemination and outgrowth by aiding the destruction of circulating or seeded MUC1-expressing tumor cells. Vaccination of breast cancer patients with MUC1-derived (glyco)peptides in an adjuvant setting may favorably influence the outcome of disease.

scholarly journals Relationship Between The Embolism and Blood Group in Cancer Patients with Deep Vein Thrombosis

2013 ◽  
Vol 3 (2) ◽  
pp. 72-75
Author(s):  
Cemil Bilir ◽  
Huseyin Engin ◽  
Yasemin Bakkal Temi ◽  
Mustafa Gurkan Haytaoglu ◽  
Sehmus Ertop
Keyword(s):  
Deep Vein Thrombosis ◽  
Cancer Patients ◽  
Blood Group ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals Anti-α Gal Antibodies in the Context of Blood Group and Stool and Tumour-Adjacent Microbiome in Colorectal Cancer Patients

2019 ◽  
Vol 30 ◽  
pp. xi60
Author(s):  
I. Selingerova ◽  
E. Budinska ◽  
B. Zwinsova ◽  
B. Mazalova ◽  
B. Bencsikova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Blood Group ◽  
Colorectal Cancer Patients

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

Blood group distribution in prostatic cancer patients

1977 ◽  
Vol 9 (3) ◽  
pp. 289-291 ◽  
Author(s):  
Zew Wajsman ◽  
Jack Saroff ◽  
Gerald P. Murphy
Keyword(s):  
Cancer Patients ◽  
Blood Group ◽  
Prostatic Cancer ◽  
Group Distribution

scholarly journals Relationship between ABO blood group and breast cancer at AL-Nassyria city / Iraq

2008 ◽  
pp. 26-29
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cancer Patients ◽  
Blood Group ◽  
High Frequency ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Control Samples

The current study included 200 patients with breast cancer that resemble to patient samples were collected from AL-Nassyria hospital also 279 samples as control which was collected from blood bank at ALNassiryia province . The study attempted to correlate ABO blood group with incidence to breast cancer .The results shown that type A of ABO blood group high frequency then followed by type O with in AL-Nassyria region also the results reported that A, B, O and AB blood groups frequencies of patient samples percentage were 60%, 20%, 10% and 10% respectively as well as the ABO blood groups frequencies of control samples percentage were 26%, 28%,38% and 8% respectively. The results observed there is high significant differences between ABO blood group frequencies of cancer patients and ABO blood group frequencies of control samples .The results indicated that the blood type should be considered one of risk factor as well as regarded as preclinical marker.

Sign in / Sign up

Export Citation Format

Share Document